Expert Opinion on Drug Delivery最新文献_第4页

Advances in soft mist inhalers. 软雾吸入器的进展。

IF 6.6 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-07-10 DOI: 10.1080/17425247.2023.2231850

Varsha Komalla, Chun Yuen Jerry Wong, Imco Sibum, Bernhard Muellinger, Wietze Nijdam, Vishal Chaugule, Julio Soria, Hui Xin Ong, Nicolas A Buchmann, D Traini

{"title":"Advances in soft mist inhalers.","authors":"Varsha Komalla, Chun Yuen Jerry Wong, Imco Sibum, Bernhard Muellinger, Wietze Nijdam, Vishal Chaugule, Julio Soria, Hui Xin Ong, Nicolas A Buchmann, D Traini","doi":"10.1080/17425247.2023.2231850","DOIUrl":"10.1080/17425247.2023.2231850","url":null,"abstract":"Introduction: Soft mist inhalers (SMIs) are propellant-free inhalers that utilize mechanical power to deliver single or multiple doses of inhalable drug aerosols in the form of a slow mist to patients. Compared to traditional inhalers, SMIs allow for a longer and slower release of aerosol with a smaller ballistic effect, leading to a limited loss in the oropharyngeal area, whilst requiring little coordination of actuation and inhalation by patients. Currently, the Respimat® is the only commercially available SMI, with several others in different stages of preclinical and clinical development.Areas covered: The primary purpose of this review is to critically assess recent advances in SMIs for the delivery of inhaled therapeutics.Expert opinion: Advanced particle formulations, such as nanoparticles which target specific areas of the lung, Biologics, such as vaccines, proteins, and antibodies (which are sensitive to aerosolization), are expected to be generally delivered by SMIs. Furthermore, repurposed drugs are expected to constitute a large share of future formulations to be delivered by SMIs. SMIs can also be employed for the delivery of formulations that target systemic diseases. Finally, digitalizing SMIs would improve patient adherence and provide clinicians with fundamental insights into patients' treatment progress.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1055-1070"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9764523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

GPP-TSAIII nanocomposite hydrogel-based photothermal ablation facilitates melanoma therapy. 基于GPP-TSAII纳米复合水凝胶的光热消融促进了黑色素瘤的治疗。

IF 6.6 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-06-12 DOI: 10.1080/17425247.2023.2200997

Xing Huang, Yihao He, Miao Zhang, Zhenhui Lu, Tong Zhang, Bing Wang

{"title":"GPP-TSAIII nanocomposite hydrogel-based photothermal ablation facilitates melanoma therapy.","authors":"Xing Huang, Yihao He, Miao Zhang, Zhenhui Lu, Tong Zhang, Bing Wang","doi":"10.1080/17425247.2023.2200997","DOIUrl":"10.1080/17425247.2023.2200997","url":null,"abstract":"Background: Photothermal therapy (PTT) is a promising cancer treatment, but its application is limited by low photoconversion efficiency. In this study, we aimed to develop a novel graphene oxide (GO)-based nanocomposite hydrogel to improve the bioavailability of timosaponin AIII (TSAIII) while maximizing PTT efficacy and enhancing the antitumor effect.Methods: GO was modified via physical cross-linking with polyvinyl alcohol. The pore structure of the gel was adjusted by repeated freeze-thawing and the addition of polyethylene glycol 2000 to obtain a nanocomposite hydrogel (GPP). The GPP loaded with TSAIII constituted a GPP-TSAIII drug delivery system, and its efficacy was evaluated by in vitro cytotoxicity, apoptosis, migration, and uptake analyses, and in vivo antitumor studies.Results: The encapsulation rate of GPP-TSAIII was 66.36 ± 3.97%, with slower in vitro release and higher tumor cell uptake (6.4-fold) compared to TSAIII. GPP-TSAIII in combination with PTT showed better bioavailability and antitumor effects in vivo than did TSAIII, with a 1.9-fold higher tumor suppression rate than the TSAIII group.Conclusions: GPP is a potential vehicle for delivery of TSAIII-like poor water-soluble anticancer drugs. The innovative PTT co-delivery system may serve as a safe and effective melanoma treatment platform for further anticancer translational purposes.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1277-1295"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9977525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Receptor-mediated transcytosis of macromolecules across the blood-brain barrier. 受体介导的大分子跨血脑屏障转运。

IF 6.6 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-09-15 DOI: 10.1080/17425247.2023.2255138

Habib Baghirov

{"title":"Receptor-mediated transcytosis of macromolecules across the blood-brain barrier.","authors":"Habib Baghirov","doi":"10.1080/17425247.2023.2255138","DOIUrl":"10.1080/17425247.2023.2255138","url":null,"abstract":"Introduction: The blood-brain barrier (BBB) restricts brain access of virtually all macromolecules. Receptor-mediated transcytosis (RMT) is one strategy toward their brain delivery. In this strategy, targeting ligands conjugated to therapeutic payload or decorating particles containing the payload interact with targets on brain capillary endothelial cells (BCEC), triggering internalization, trafficking, and release from BCEC.Areas covered: RMT at the BBB has leveraged multiple formats of macromolecules and large particles. Interactions between those and BCEC have been studied primarily using antibodies, with findings applicable to the design of larger particles. BBB-penetrant constructs have also been identified in screening campaigns and directed evolution, and subsequently found to interact with RMT targets. In addition, BCEC targeted by constructs incorporating genomic payload can be made to produce therapeutic proteins.Expert opinion: While targeting may not be strictly necessary to reach a therapeutic effect for all macromolecules, it can improve a molecule's BBB transport, exposing it to the entire brain parenchyma and enhancing its effect. Constructs with better BCEC transcytosis may be designed rationally, leveraging knowledge about BCEC trafficking, and found in screening campaigns, where this knowledge can reduce the search space and improve iterative refinement. Identification of new targets may also help generate BBB-crossing constructs.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1699-1711"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10229954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nose to brain delivery of naringin-loaded chitosan nanoparticles for potential use in oxaliplatin-induced chemobrain in rats: impact on oxidative stress, cGAS/STING and HMGB1/RAGE/TLR2/MYD88 inflammatory axes. 从鼻腔到大脑输送柚皮苷壳聚糖纳米颗粒，用于奥沙利铂诱导的大鼠化疗脑：对氧化应激、cGAS/STING 和 HMGB1/RAGE/TLR2/MYD88 炎症轴的影响。

IF 6.6 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-06-27 DOI: 10.1080/17425247.2023.2228685

Diana M F Hanna, John Youshia, Sarah Farid Fahmy, Mina Y George

{"title":"Nose to brain delivery of naringin-loaded chitosan nanoparticles for potential use in oxaliplatin-induced chemobrain in rats: impact on oxidative stress, cGAS/STING and HMGB1/RAGE/TLR2/MYD88 inflammatory axes.","authors":"Diana M F Hanna, John Youshia, Sarah Farid Fahmy, Mina Y George","doi":"10.1080/17425247.2023.2228685","DOIUrl":"10.1080/17425247.2023.2228685","url":null,"abstract":"Objectives: Oxaliplatin induces chemobrain in cancer patients/survivors. Nutraceutical naringin has antioxidant and anti-inflammatory properties with low oral bioavailability. Our aim was to formulate naringin in chitosan nanoparticles for nose to brain delivery and assess its neuroprotective effect against oxaliplatin-induced chemobrain in rats.Methods: Naringin chitosan nanoparticles were prepared by ionic gelation. Rats were administered oral naringin (80 mg/kg), intranasal naringin (0.3 mg/kg) or intranasal naringin-loaded chitosan nanoparticles (0.3 mg/kg). Naringin's neuroprotective efficacy was assessed based on behavioral tests, histopathology, and measuring oxidative stress and inflammatory markers.Results: Selected nanoparticles formulation showed drug loading of 5%, size of 150 nm and were cationic. Intranasal naringin administration enhanced memory function, inhibited hippocampal acetylcholinesterase activity, and corrected oxaliplatin-induced histological changes. Moreover, it reduced malondialdehyde and elevated reduced glutathione hippocampal levels. Furthermore, it decreased levels of inflammatory markers: NF-kB and TNF-α by 1.25-fold. Upstream to this inflammatory status, intranasal naringin downregulated the hippocampal protein levels of two pathways: cGAS/STING and HMGB1/RAGE/TLR2/MYD88.Conclusion: Intranasal naringin-loaded chitosan nanoparticles showed superior amelioration of oxaliplatin-induced chemobrain in rats at a dose 267-fold lower to that administered orally. The potential involvement of cGAS/STING and HMGB1/RAGE/TLR2/MYD88 pathways in the mechanistic process of either oxaliplatin-induced chemobrain or naringin-mediated neuroprotection was evidenced.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1859-1873"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10125287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Barriers for orally inhaled therapeutic antibodies. 口服吸入治疗性抗体的屏障。

IF 6.6 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-08-25 DOI: 10.1080/17425247.2023.2249821

Thomas Sécher, Nathalie Heuzé-Vourc'h

{"title":"Barriers for orally inhaled therapeutic antibodies.","authors":"Thomas Sécher, Nathalie Heuzé-Vourc'h","doi":"10.1080/17425247.2023.2249821","DOIUrl":"10.1080/17425247.2023.2249821","url":null,"abstract":"Introduction: Respiratory diseases represent a worldwide health issue. The recent Sars-CoV-2 pandemic, the burden of lung cancer, and inflammatory respiratory diseases urged the development of innovative therapeutic solutions. In this context, therapeutic antibodies (Abs) offer a tremendous opportunity to benefit patients with respiratory diseases. Delivering Ab through the airways has been demonstrated to be relevant to improve their therapeutic index. However, few inhaled Abs are on the market.Areas covered: This review describes the different barriers that may alter the fate of inhaled therapeutic Abs in the lungs at steady state. It addresses both physical and biological barriers and discusses the importance of taking into consideration the pathological changes occurring during respiratory disease, which may reinforce these barriers.Expert opinion: The pulmonary route remains rare for delivering therapeutic Abs, with few approved inhaled molecules, despite promising evidence. Efforts must focus on the intertwined barriers associated with lung diseases to develop appropriate Ab-formulation-device combo, ensuring optimal Ab deposition in the respiratory tract. Finally, randomized controlled clinical trials should be carried out to establish inhaled Ab therapy as prominent against respiratory diseases.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1071-1084"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10066866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting cerebral diseases with enhanced delivery of therapeutic proteins across the blood-brain barrier. 通过加强血脑屏障上治疗蛋白质的输送，靶向治疗脑部疾病。

IF 6.6 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-03-30 DOI: 10.1080/17425247.2023.2193390

Yanning Bao, Weiyue Lu

{"title":"Targeting cerebral diseases with enhanced delivery of therapeutic proteins across the blood-brain barrier.","authors":"Yanning Bao, Weiyue Lu","doi":"10.1080/17425247.2023.2193390","DOIUrl":"10.1080/17425247.2023.2193390","url":null,"abstract":"Introduction: Cerebral diseases have been threatening public physical and psychological health in the recent years. With the existence of the blood-brain barrier (BBB), it is particularly hard for therapeutic proteins like peptides, enzymes, antibodies, etc. to enter the central nervous system (CNS) and function in diagnosis and treatment in cerebral diseases. Fortunately, the past decade has witnessed some emerging strategies of delivering macromolecular therapeutic proteins across the BBB.Areas covered: Based on the structure, functions, and substances transport mechanisms, various enhanced delivery strategies of therapeutic proteins were reviewed, categorized by molecule-mediated delivery strategies, carrier-mediated delivery strategies, and other delivery strategies.Expert opinion: As for molecule-mediated delivery strategies, development of genetic engineering technology, optimization of protein expression and purification techniques, and mature of quality control systems all help to realize large-scale production of recombinant antibodies, making it possible to apply to the clinical practice. In terms of carrier-mediated delivery strategies and others, although nano-carriers/adeno-associated virus (AAV) are also promising candidates for delivering therapeutic proteins or genes across the BBB, some issues still remain to be further investigated, including safety concerns related to applied materials, large-scale production costs, quality control standards, combination therapies with auxiliary delivery strategies like focused ultrasound, etc.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1681-1698"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9625442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral administration of M13-loaded nanoliposomes is safe and effective to treat colitis-associated cancer in mice. 口服M13负载纳米脂质体治疗小鼠结肠炎相关癌症是安全有效的。

IF 5 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-07-02 DOI: 10.1080/17425247.2023.2231345

Dingpei Long, Zahra Alghoul, Junsik Sung, Chunhua Yang, Didier Merlin

{"title":"Oral administration of M13-loaded nanoliposomes is safe and effective to treat colitis-associated cancer in mice.","authors":"Dingpei Long, Zahra Alghoul, Junsik Sung, Chunhua Yang, Didier Merlin","doi":"10.1080/17425247.2023.2231345","DOIUrl":"10.1080/17425247.2023.2231345","url":null,"abstract":"Objective: Colitis-associated cancer (CAC) treatment lacks effective small-molecule drugs and efficient targeted delivery systems. Here, we loaded M13 (an anti-cancer drug candidate) to colon-targeting ginger-derived nanoliposomes (NL) and investigated if orally administered M13-NL could enhance the anticancer effects of M13 in CAC mouse models.Methods: The biopharmaceutical properties of M13 were assessed by physicochemical characterizations. The in vitro immunotoxicity of M13 was assessed against PBMCs using FACS and the mutagenic potential of M13 was evaluated by the Ames assay. The in vitro efficacy of M13 was tested in 2D- and 3D-cultured cancerous intestinal cells. AOM/DSS-induced CAC mice were used to evaluate the therapeutic effects of free M13 or M13-NL on CAC in vivo.Results: M13 has beneficial physiochemical properties, including high stability, and no apparent immunotoxicity or mutagenic potential in vitro. M13 is effective against the growth of 2D- and 3D-cultured cancerous intestinal cells in vitro. The in vivo safety and efficacy of M13 were significantly improved by using NL for drug delivery (p < 0.001). Oral administration of M13-NL exhibited excellent therapeutic effects in AOM/DSS-induced CAC mice.Conclusion: M13-NL is a promising oral drug formulation for CAC treatment.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1443-1462"},"PeriodicalIF":5.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10810011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10095905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delivering monoclonal antibodies via inhalation: a systematic review of clinical trials in asthma and COPD. 通过吸入递送单克隆抗体：哮喘和慢性阻塞性肺病临床试验的系统综述。

IF 6.6 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-06-27 DOI: 10.1080/17425247.2023.2228681

Rossella Laitano, Luigino Calzetta, Francesco Cavalli, Mario Cazzola, Paola Rogliani

{"title":"Delivering monoclonal antibodies via inhalation: a systematic review of clinical trials in asthma and COPD.","authors":"Rossella Laitano, Luigino Calzetta, Francesco Cavalli, Mario Cazzola, Paola Rogliani","doi":"10.1080/17425247.2023.2228681","DOIUrl":"10.1080/17425247.2023.2228681","url":null,"abstract":"Introduction: Advances in understanding the pathophysiology of asthma and chronic obstructive pulmonary disease (COPD) led to investigation of biologic drugs targeting specific inflammatory pathways. No biologics are licensed for COPD while all the approved monoclonal antibodies (mAbs) for severe asthma treatment are systemically administered. Systemic administration is associated with low target tissue exposure and risk of systemic adverse events. Thus, delivering mAbs via inhalation may be an attractive approach for asthma and COPD treatment due to direct targeting of the airways.Areas covered: This systematic review of randomized control trials (RCTs) evaluated the potential role of delivering mAbs via inhalation in asthma and COPD treatment. Five RCTs were deemed eligible for a qualitative analysis.Expert opinion: Compared to systemic administration, delivering mAbs via inhalation is associated with rapid onset of action, greater efficacy at lower doses, minimal systemic exposure, and lower risk of adverse events. Although some of the inhaled mAbs included in this study showed a certain level of efficacy and safety in asthmatic patients, delivering mAbs via inhalation is still challenging and controversial. Further adequately powered and well-designed RCTs are needed to assess the potential role of inhaled mAbs in the treatment of asthma and COPD.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1041-1054"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10062840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery. 靶向肠道微生物组以控制药物药物微生物组学：口服给药的下一个前沿。

IF 6.6 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-07-07 DOI: 10.1080/17425247.2023.2233900

Srinivas Kamath, Andrea M Stringer, Clive A Prestidge, Paul Joyce

{"title":"Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery.","authors":"Srinivas Kamath, Andrea M Stringer, Clive A Prestidge, Paul Joyce","doi":"10.1080/17425247.2023.2233900","DOIUrl":"10.1080/17425247.2023.2233900","url":null,"abstract":"Introduction: The trillions of microorganisms that comprise the gut microbiome form dynamic bidirectional interactions with orally administered drugs and host health. These relationships can alter all aspects of drug pharmacokinetics and pharmacodynamics (PK/PD); thus, there is a desire to control these interactions to maximize therapeutic efficacy. Attempts to modulate drug-gut microbiome interactions have spurred advancements within the field of 'pharmacomicrobiomics' and are poised to become the next frontier of oral drug delivery.Areas covered: This review details the bidirectional interactions that exist between oral drugs and the gut microbiome, with clinically relevant case examples outlining a clear motive for controlling pharmacomicrobiomic interactions. Specific focus is attributed to novel and advanced strategies that have demonstrated success in mediating drug-gut microbiome interactions.Expert opinion: Co-administration of gut-active supplements (e.g. pro- and pre-biotics), innovative drug delivery vehicles, and strategic polypharmacy serve as the most promising and clinically viable approaches for controlling pharmacomicrobiomic interactions. Targeting the gut microbiome through these strategies presents new opportunities for improving therapeutic efficacy by precisely mediating PK/PD, while mitigating metabolic disturbances caused by drug-induced gut dysbiosis. However, successfully translating preclinical potential into clinical outcomes relies on overcoming key challenges related to interindividual variability in microbiome composition and study design parameters.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1315-1331"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9761673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Challenges and opportunities in delivering oral peptides and proteins. 口服肽和蛋白质递送的挑战和机遇。

IF 6.6 2区医学

Expert Opinion on Drug Delivery Pub Date : 2023-07-01 Epub Date: 2023-07-17 DOI: 10.1080/17425247.2023.2237408

Haisheng Peng, Jiahe Wang, Jiayu Chen, Yanbo Peng, Xiaoxian Wang, Ying Chen, David L Kaplan, Qun Wang

{"title":"Challenges and opportunities in delivering oral peptides and proteins.","authors":"Haisheng Peng, Jiahe Wang, Jiayu Chen, Yanbo Peng, Xiaoxian Wang, Ying Chen, David L Kaplan, Qun Wang","doi":"10.1080/17425247.2023.2237408","DOIUrl":"10.1080/17425247.2023.2237408","url":null,"abstract":"Introduction: Rapid advances in bioengineering enable the use of complex proteins as therapeutic agents to treat diseases. Compared with conventional small molecule drugs, proteins have multiple advantages, including high bioactivity and specificity with low toxicity. Developing oral dosage forms with active proteins is a route to improve patient compliance and significantly reduce production costs. However, the gastrointestinal environment remains a challenge to this delivery path due to enzymatic degradation, low permeability, and weak absorption, leading to reduced delivery efficiency and poor clinical outcomes.Areas covered: This review describes the barriers to oral delivery of peptides and complex proteins, current oral delivery strategies utilized and the opportunities and challenges ahead to try and circumvent these barriers. Oral protein drugs on the market and clinical trials provide insights and approaches for advancing delivery strategies.Expert opinion: Although most current studies on oral protein delivery rely on in vitro and in vivo animal data, the safety and limitations of the approach in humans remain uncertain. The shortage of clinical data limits the development of new or alternative strategies. Therefore, designing appropriate oral delivery strategies remains a significant challenge and requires new ideas, innovative design strategies and novel model systems.","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":" ","pages":"1349-1369"},"PeriodicalIF":6.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9826380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0